Lucis raised a $20 million Series A this month, which is unremarkable until you notice the company was founded in 2025 and raised its $8 million seed only four months earlier. That’s not a funding round, that’s a company being chased. Singular led, with General Catalyst and Y Combinator following, bringing the total to $28 million for a company barely a year old.

The product is preventive health, a category with a graveyard’s worth of wellness-adjacent flops behind it. Lucis’s version is more clinical than most: it analyses more than 110 blood biomarkers across metabolic health, hormones, cardiovascular risk, inflammation and nutrient levels, feeds the results into an AI companion app, and, crucially, has physicians review the guidance before it reaches you. The pitch from co-founder Maxime Berthelot is that “the science is already there; what’s missing is a system designed to act before symptoms appear.”

At first test, 99.9% of Lucis users had at least one biomarker outside the optimal range, usually without knowing it. Either everyone is quietly unwell, or “optimal” is a marketing range. Probably a bit of both, and either way it sells retests.

The traction data is the kind that makes investors move fast. Among users who did a six-month follow-up, 75% improved at least three biomarkers without medication, and more than 80% chose to retest, which, in a category defined by people trying something once and forgetting it, is the metric that matters. Over 10,000 users across France, the UK, Ireland and Portugal, more than a million biomarker tests run, lab partnerships with Eurofins and Randox.

The skeptic’s note writes itself: a platform that tells 99.9% of users something is “off” and then sells them the retest has an incentive structure worth watching, and “prevention” is easier to sell than to prove over a decade. But the European framing is genuinely sharp, Berthelot wants prevention to be “the default, rather than a privilege”, and a Paris company going from zero to a chased Series A in a year, with Spain, Germany and Italy next, is exactly the kind of compounding this continent keeps producing.

You’ve used Prelude’s category a hundred times without thinking about it: the SMS verification code that lands on your phone when you log in or sign up. It feels like a solved, trivial thing. It is neither. Delivering those codes reliably across the world’s telecom networks is genuinely hard, and the system is quietly riddled with fraud, including schemes that exist purely to pump up SMS traffic for profit. Prelude, based in Paris and founded in 2022, raised a $20 million Series A to be the infrastructure layer that gets this right.

The round was led by 20VC, the fund founded by Harry Stebbings, with existing investors Singular, Seedcamp and Deel joining, Deel’s involvement being notable, since a global payroll company is exactly the kind of customer that sends millions of verification messages and bleeds money when they fail or get gamed. The money goes toward scaling Prelude’s trust infrastructure, deepening telecom partnerships, expanding API coverage across Europe, and investing in machine-learning fraud detection.

The best infrastructure businesses are the ones nobody notices until they break. Prelude is betting that “verification” is one of them, boring, essential, and worth a toll on every login.

This is, deliberately, unglamorous. There’s no consumer brand, no viral moment, no AI demo that makes people gasp. There’s a hard technical problem, reliable, fraud-resistant verification at global scale, and a company quietly building the rails for it and charging the developers who’d rather not. That’s a perfectly good business model; it’s roughly the one Twilio built an empire on.

The European read is the recurring one in these stories: this is the kind of essential, infrastructure-grade software that doesn’t make headlines but does make money, and Paris keeps producing it. Prelude faces real competition from incumbents and from the telecom layer itself, and “verification infrastructure” is a category where trust and reliability take years to earn. But a $20 million Series A with Deel on the cap table is a credible start, and another quiet brick in the European tech story the pessimists keep failing to notice.